Correlation Between Enorama Pharma and Vicore Pharma

Can any of the company-specific risk be diversified away by investing in both Enorama Pharma and Vicore Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Enorama Pharma and Vicore Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Enorama Pharma AB and Vicore Pharma Holding, you can compare the effects of market volatilities on Enorama Pharma and Vicore Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Enorama Pharma with a short position of Vicore Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Enorama Pharma and Vicore Pharma.

Diversification Opportunities for Enorama Pharma and Vicore Pharma

-0.04

Correlation Coefficient

Enorama Pharma  Vicore Pharma

Good diversification

The 3 months correlation between Enorama and Vicore is -0.04. Overlapping area represents the amount of risk that can be diversified away by holding Enorama Pharma AB and Vicore Pharma Holding in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Vicore Pharma Holding and Enorama Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Enorama Pharma AB are associated (or correlated) with Vicore Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Vicore Pharma Holding has no effect on the direction of Enorama Pharma i.e., Enorama Pharma and Vicore Pharma go up and down completely randomly.

Pair Corralation between Enorama Pharma and Vicore Pharma

Assuming the 90 days trading horizon Enorama Pharma AB is expected to under-perform the Vicore Pharma. In addition to that, Enorama Pharma is 1.66 times more volatile than Vicore Pharma Holding. It trades about -0.03 of its total potential returns per unit of risk. Vicore Pharma Holding is currently generating about 0.05 per unit of volatility. If you would invest  827.00  in Vicore Pharma Holding on October 25, 2024 and sell it today you would earn a total of  48.00  from holding Vicore Pharma Holding or generate 5.8% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Enorama Pharma AB  vs.  Vicore Pharma Holding

Enorama Pharma AB

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Enorama Pharma AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest uncertain performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

Vicore Pharma Holding

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Vicore Pharma Holding are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Vicore Pharma may actually be approaching a critical reversion point that can send shares even higher in February 2025.

Pair Trading with Enorama Pharma and Vicore Pharma

The main advantage of trading using opposite Enorama Pharma and Vicore Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Enorama Pharma position performs unexpectedly, Vicore Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vicore Pharma will offset losses from the drop in Vicore Pharma's long position.

The idea behind Enorama Pharma AB and Vicore Pharma Holding pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.